Roads to remission : evolving treatment concepts in type 2 inflammatory diseases
- Author
- Marek Lommatzsch, Katharina Blumchen, Lisa A. Beck, Jean Bousquet, Guy Brusselle (UGent) , Wytske J. Fokkens, Eckard Hamelmann, Susanne Lau, Hagen Ott, Oliver Pfaar, Hugh A. Sampson, Josef S. Smolen, Christian Taube, Ingo H. Tarner, Martin Wagenmann, Thomas Werfel, Margitta Worm and Harald Renz
- Organization
- Abstract
- Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs.
- Keywords
- Remission, Disease modification, Type 2 inflammation, C-REACTIVE PROTEIN, RHEUMATOID-ARTHRITIS, CHRONIC RHINOSINUSITIS, ATOPIC-DERMATITIS, ALLERGEN IMMUNOTHERAPY, ASTHMA CONTROL, EOSINOPHILIC ESOPHAGITIS, TREATMENT STRATEGY, ACTIVITY INDEX, VALIDATION
Downloads
-
RTR.pdf
- full text (Published version)
- |
- open access
- |
- |
- 586.69 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01JH7Z0WZNAT1W3Q85WEQ98HZM
- MLA
- Lommatzsch, Marek, et al. “Roads to Remission : Evolving Treatment Concepts in Type 2 Inflammatory Diseases.” ECLINICALMEDICINE, vol. 80, 2025, doi:10.1016/j.eclinm.2024.103050.
- APA
- Lommatzsch, M., Blumchen, K., Beck, L. A., Bousquet, J., Brusselle, G., Fokkens, W. J., … Renz, H. (2025). Roads to remission : evolving treatment concepts in type 2 inflammatory diseases. ECLINICALMEDICINE, 80. https://doi.org/10.1016/j.eclinm.2024.103050
- Chicago author-date
- Lommatzsch, Marek, Katharina Blumchen, Lisa A. Beck, Jean Bousquet, Guy Brusselle, Wytske J. Fokkens, Eckard Hamelmann, et al. 2025. “Roads to Remission : Evolving Treatment Concepts in Type 2 Inflammatory Diseases.” ECLINICALMEDICINE 80. https://doi.org/10.1016/j.eclinm.2024.103050.
- Chicago author-date (all authors)
- Lommatzsch, Marek, Katharina Blumchen, Lisa A. Beck, Jean Bousquet, Guy Brusselle, Wytske J. Fokkens, Eckard Hamelmann, Susanne Lau, Hagen Ott, Oliver Pfaar, Hugh A. Sampson, Josef S. Smolen, Christian Taube, Ingo H. Tarner, Martin Wagenmann, Thomas Werfel, Margitta Worm, and Harald Renz. 2025. “Roads to Remission : Evolving Treatment Concepts in Type 2 Inflammatory Diseases.” ECLINICALMEDICINE 80. doi:10.1016/j.eclinm.2024.103050.
- Vancouver
- 1.Lommatzsch M, Blumchen K, Beck LA, Bousquet J, Brusselle G, Fokkens WJ, et al. Roads to remission : evolving treatment concepts in type 2 inflammatory diseases. ECLINICALMEDICINE. 2025;80.
- IEEE
- [1]M. Lommatzsch et al., “Roads to remission : evolving treatment concepts in type 2 inflammatory diseases,” ECLINICALMEDICINE, vol. 80, 2025.
@article{01JH7Z0WZNAT1W3Q85WEQ98HZM,
abstract = {{Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs.}},
articleno = {{103050}},
author = {{Lommatzsch, Marek and Blumchen, Katharina and Beck, Lisa A. and Bousquet, Jean and Brusselle, Guy and Fokkens, Wytske J. and Hamelmann, Eckard and Lau, Susanne and Ott, Hagen and Pfaar, Oliver and Sampson, Hugh A. and Smolen, Josef S. and Taube, Christian and Tarner, Ingo H. and Wagenmann, Martin and Werfel, Thomas and Worm, Margitta and Renz, Harald}},
issn = {{2589-5370}},
journal = {{ECLINICALMEDICINE}},
keywords = {{Remission,Disease modification,Type 2 inflammation,C-REACTIVE PROTEIN,RHEUMATOID-ARTHRITIS,CHRONIC RHINOSINUSITIS,ATOPIC-DERMATITIS,ALLERGEN IMMUNOTHERAPY,ASTHMA CONTROL,EOSINOPHILIC ESOPHAGITIS,TREATMENT STRATEGY,ACTIVITY INDEX,VALIDATION}},
language = {{eng}},
pages = {{13}},
title = {{Roads to remission : evolving treatment concepts in type 2 inflammatory diseases}},
url = {{http://doi.org/10.1016/j.eclinm.2024.103050}},
volume = {{80}},
year = {{2025}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: